Goldberg, S. B., Redman, M. W., Camidge, D. R., Minichiello, K., Highleyman, L., Patel, J. D., Stinchcombe, T., Bradley, J. D., Brahmer, J. R., Borghaei, H., Gray, J. E., Waqar, S. N., Reckamp, K. L., Herbst, R. S., Kelly, K., Ross, H. J. (2026). A randomized phase II study of capmatinib plus osimertinib with or without ramucirumab in patients with
                    <i>EGFR</i>
                    -mutant,
                    <i>MET</i>
                    -amplified stage IV or recurrent no–small cell lung cancer (Lung-MAP Sub-Study S1900G).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps8677